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Imprinted genes are expressed primarily from one parental allele by virtue of a germ line epigenetic
process. Achaete-scute complex homolog 2 (Ascl2 aka Mash2) is a maternally expressed imprinted gene
that plays a key role in placental and intestinal development. Loss-of-function of Ascl2 results in an
expansion of the parietal trophoblast giant cell (P-TGC) lineage, an almost complete loss of Trophoblast
speciﬁc protein alpha (Tpbpa) positive cells in the ectoplacental cone and embryonic failure by E10.5.
Tpbpa expression marks the progenitors of some P-TGCs, two additional trophoblast giant cell lineages
(spiral artery and canal), the spongiotrophoblast and the glycogen cell lineage. Using a transgenic model,
here we show that elevated expression of Ascl2 reduced the number of P-TGC cells by 40%. Elevated Ascl2
also resulted in a marked loss of the spongiotrophoblast and a substantial mislocalisation of glycogen
cells into the labyrinth. In addition, Ascl2-Tg placenta contained considerably more placental glycogen
than wild type. Glycogen cells are normally located within the junctional zone in close contact with
spongiotrophoblast cells, before migrating through the P-TGC layer into the maternal decidua late in
gestation where their stores of glycogen are released. The failure of glycogen cells to release their stores
of glycogen may explain both the inappropriate accumulation of glycogen and fetal growth restriction
observed late in gestation in this model. In addition, using in a genetic cross we provide evidence that
Ascl2 requires the activity of a second maternally expressed imprinted gene, Pleckstrin homology-like
domain, family a, member 2 (Phlda2) to limit the expansion of the spongiotrophoblast. This “belts and
braces” approach demonstrates the importance of genomic imprinting in regulating the size of the
placental endocrine compartment for optimal placental development and fetal growth.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Genomic imprinting is a remarkable process whereby certain
genes are preferentially silenced on one parental allele as a con-
sequence of epigenetic events initiated in the germ line (Surani,
1998). Imprinted genes have been shown to functionally converge
on biological processes that, while not exclusive to mammals,
were likely important for the relative dominance of mammals on
Earth today, including placentation, advanced maturity at birth
and high maternal care (Kaneko-Ishino and Ishino, 2010; Keverne,
2013; Renfree et al., 2013; Moore, 2011; Cleaton et al., 2014; Peters,
2014). The majority of studies on imprinted genes rely on loss-of-
expression models. However, imprinting is a mechanism that ex-
clusively modulates gene dosage. Examining models in which gene
dosage is increased may further contribute to our understanding
of genomic imprinting.r Inc. This is an open access articleAchaete-scute complex homolog 2 (Ascl2 aka Mash2) was one of
the ﬁrst imprinted genes to be knocked out in mice (Guillemot
et al., 1995). These studies demonstrated that fetal survival beyond
E10.5 requires the maternal Ascl2 allele (Guillemot et al., 1995,
1994). Loss of function restricted to the embryo had no overt
consequence during gestation highlighting a requirement for
placental Ascl2 in the transition to the mature chorioallantoic
placenta (Tanaka et al., 1997). The mature mouse placenta is or-
ganised into the histologically distinct labyrinth zone, junctional
zone and maternal decidua, all of which are interspersed with
trophoblast giant cells (TGCs) (John and Hemberger, 2012; Rai and
Cross, 2014). Loss-of-function of Ascl2 resulted in an expansion of
one TGC type, the parietal (P-) TGCs. These normally form a single
layer of cells located beneath the maternal decidua surrounding
large lakes of maternal blood leading into the uterine veins, that
becomes somewhat discontinuous as development proceeds (Rai
and Cross, 2014). In Ascl2/þ placenta there were multiple layers
of P-TGCs (Guillemot et al., 1994; Tanaka et al., 1997). Four other
distinct TGC types exist which are deﬁned by their characteristicunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ternal circulation (Rai and Cross, 2014; Simmons et al., 2007, 2008;
Gasperowicz et al., 2013). The spiral artery (SpA-) TGCs are located
within the maternal decidua lining the maternal blood system on
entry to the placenta; the canal (C-) TGCs line the maternal blood
canals as they pass through the junctional zone; the sinusoidal
TGCs (S-TGCs) are in direct contact with the maternal blood spaces
within the labyrinth and the recently discovered channel (Ch-)
TGCs line the maternal blood spaces located just beneath the de-
cidua where maternal blood drains into the venous sinuses to be
returned to the maternal circulation (Rai and Cross, 2014; Sim-
mons et al., 2007, 2008; Gasperowicz et al., 2013). These additional
lineages were not examined in Ascl2/þ placenta as these fail too
early in development, but the original report (Guillemot et al.,
1994) noted an almost complete lack of expression of Trophoblast
speciﬁc protein alpha (Tpbpa). Tpbpa is expressed in the progenitor
cells of 50% of the P-TGCs, all the SpA-TGCs and C-TGCs, as well as
the glycogen cell and spongiotrophoblast lineages that form the
bulk of the junctional zone (Hu and Cross, 2011). Another mouse
model (Del7A1/þ) in which Ascl2 levels were reduced by 50%, al-
lowed survival to term and the assessment of a later placental
phenotype (Oh-McGinnis et al., 2011). Del7A1/þ placenta possessed
a similarly expanded P-TGC layer alongside a reduced spongio-
trophoblast and a complete loss of the glycogen cell lineage (Oh-
McGinnis et al., 2011; Lefebvre et al., 2009). Del7A1/þ involves
maternal inheritance of a 280 kb deletion physically adjacent to
Ascl2 and spanning the maternally expressed Tyrosine hydroxylase
(Th) gene. Consequently, these placenta lack Th expression after
maternal transmission of this deletion. Del7A1/þ placenta also ex-
press Pleckstrin Homology-Like Domain, Family A, Member 2
(Phlda2) at two-fold the normal level (Data summarised in Sup-
plemental Table 1). Phlda2 maps to the same imprinted domain at
Ascl2 and Th (Fitzpatrick et al., 2002). We have previously shown
that two-fold expression of Phlda2 results in a 50% loss of the
spongiotrophoblast lineage (Tunster et al., 2010, 2014, 2015).
Consequently the loss of spongiotrophoblast in the Del7A1/þ pla-
centa may be a direct consequence of reduced Ascl2 expression or
increased Phlda2 expression.
These in vivo studies highlighted a potential role for Ascl2 as a
dosage-sensitive cellular switch between the spongiotrophoblast/
glycogen cell lineages and the P-TGC lineage. Consistent with a
role in lineage choice, Ascl2 is expressed in the ectoplacental cone
and extra embryonic ectoderm at E7.5 where the placental pro-
genitors reside with expression restricted to the diploid tropho-
blast cells, and later diploid trophoblast cells located in the la-
byrinthine and spongiotrophoblast layers (Guillemot et al., 1994.,
1993). This model would be consistent with the ﬁnding that ec-
topic expression of Ascl2 can inhibit the normal differentiation of
Rcho-1 cells, a rat choriocarcinoma cell line, towards a TGC-like
fate (Kraut et al., 1998; Cross et al., 1995; Hughes et al., 2004).
However, ectopic expression of Ascl2 in trophoblast stem (TS) cells,
which can differentiate into a number of trophoblast lineages,
resulted in decreased expression of both Prl3d, a marker of TGCs,
and Tpbpa, a gene expressed in the progenitors of a number of
lineages including the spongiotrophoblast, suggesting that Ascl2
could function to repress more than one placental lineage (Hughes
et al., 2004; Takao et al., 2012). The consequences of increased
expression of Ascl2 in vivo on placental development have not
been fully explored. A P1 transgene spanning the genomic locus
expressing Ascl2 at 4–7 fold the endogenous level was shown to
rescue embryonic lethality associated with maternal inheritance of
the Ascl2 targeted allele, but no overt consequence for placental or
fetal weight were reported (Rentsendorj et al., 2010). To in-
vestigate the effect of Ascl2 overexpression on placental develop-
ment and fetal growth, we made use of an existing line of mice
carrying a bacterial artiﬁcial chromosome (BAC) spanning theAscl2 locus previously used to explore the relevance of elevated
Ascl2 in intestinal tumorigenesis (Reed et al., 2012). We observed a
reciprocal relationship between Ascl2 expression and P-TGC
number as anticipated, but a marked loss of spongiotrophoblast
arguing against a role for Ascl2 as a simple cell fate switch.2. Materials and methods
2.1. Mouse strains and genotyping
All animal studies and breeding was approved by the Uni-
versities of Cardiff ethical committee and performed under a UK
Home Ofﬁce project license (RMJ). Mice were housed in a con-
ventional unit on a 12-h light–dark cycle with lights coming on at
06.00 h with a temperature range of 21 °C 72 with free access to
tap water and standard chow unless otherwise stated. The Ascl2
BAC transgenic line (Ascl2-Tg; Genome Systems BAC225J16) de-
scribed previously (Reed et al., 2012) was primarily studied on the
C57BL/6 (BL6) strain background. Some experiments were per-
formed when the transgene was bred into 129S2/SvHsd (G6; 129).
The Phlda2 targeted allele (Frank et al., 2002) was maintained by
paternal transmission on the BL6 genetic background.
2.2. Weighing studies
Embryonic and placental wet weights were taken following
careful dissection to remove the yolk sac, umbilicus and excess
decidua prior to RNA extraction at the stated time points after a
discernable plug. Genotyping data was obtained from yolk sac
DNA using primers CACATACGTTCCGCCATTCC and CCACTT-
CAACGTAACACCGC to amplify from the BAC.
2.3. Quantitative RNA analysis
Quantitative PCR of reverse transcribed RNA (QRT-PCR) was
performed as described (Tunster et al., 2010) with additional pri-
mers (Supplemental Table 2).
2.4. In situ hybridisation and histological analyses
Placentas were ﬁxed overnight in phosphate-buffered 4% par-
aformaldehyde, parafﬁn-embedded and 10 mm sections taken
through the midline. Haematoxylin and eosin (H&E) staining, ri-
boprobe preparation, in situ hybridizations and PAS staining were
performed as previously described (Tunster et al., 2010; John et al.,
2001). Biochemical determination of glycogen was performed on
fresh snap-frozen placenta as previously described (Tunster et al.,
2010; John et al., 2001). Measurements were taken from midline
sections obtained by cutting a number of serial sections and jud-
ging overall thickness as previously described (Tunster et al.,
2010). For counting P-TGC, sections were analysed without
knowing the genotype, with independent repeat blind counts.
2.5. Statistical analyses
Statistical signiﬁcance (Probability values) was determined
using the Student's t-Test (two tailed distribution and two sample
unequal variance). The signiﬁcance in the difference in observed
over the expected appearance of a particular genotype was de-
termined using the Chi-squared Test.
3. Results
The previously described transgenic line (Reed et al., 2012)
carries a bacterial artiﬁcial chromosome physically encompassing
Fig. 1. Spatially and temporally accurate (entopic) overexpression of Ascl2 in the
mouse placenta. (A) Schematic of the BAC transgene. Top line shows a genomic
map of the IC2 region on distal mouse chromosome 7. Hatched region marks the
KvDMR1 that is methylated only on the maternal allele. Arrows indicate direction of
transcription. Below is a map of the BAC transgene containing the Ascl2 gene. Filled
boxes represent imprinted genes (not to scale). (B) Placental RT-QPCR results for
Ascl2 in transgenic placenta at E9.5, E10.5 and E12.5. N¼4 placenta per genotype (2
versus 2 from 2 independent litters); error bars represent SEM. Statistical sig-
niﬁcance calculated using t-test. **Po0.01, ***Po0.005. (C) In situ hybridisation of
midline placental sections with Ascl2 riboprobe reveals similar spatial localisation
of mRNA in control and Ascl2-Tg placentas at E10.5 and E12.5. Scale bars¼200 mm.
Data for Fig. 2 in Supplemental Table 2.
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placenta were found to express Ascl2 at 6-fold the wild type
level (Fig. 1B, Supplemental Table 3). The transgene spanned a
second gene, Tspan32, not expressed in the placenta (Gartlan et al.,
2010; Nicholson et al., 2000) and not ectopically expressed from
the transgene (Supplemental Fig. 1). In situ hybridisation with an
Ascl2 riboprobe demonstrated the correct localisation of the Ascl2
signal within Ascl2-Tg placenta to a subset of diploid cells in the
ectoplacental cone and chorion at E10.5 and restricted expressionwithin a subset of cells within the junctional zone at E12.5
(Fig. 1C). Previously, adenovirus driven overexpression of Ascl2 at
10-fold the normal level was found to down-regulate expression of
both Tpbpa and Prl3d1 in trophoblast stem cells cultured under
stem cell conditions, alongside reduced expression of Phlda2 (Ta-
kao et al., 2012) (Supplemental Table 1). The spatio-temporally
accurate elevated expression of Ascl2 in this animal model pro-
vided a tool to explore the consequences of similarly increased
Ascl2 dosage on placental development in vivo.
At E10.5, P-TGC form a distinct and histologically recognisable
single cell layer between the maternal decidua and the developing
chorio-allantoic placenta. Haematoxylin staining of E10.5 Ascl2-Tg
midline placental sections revealed a marked loss of the giant,
polyploid cells lining the maternal decidua (Fig. 2A). In situ hy-
bridisation with Prl3d (Pl1), exclusively expressed in the P-TGC
lineage at this time point (Jackson et al., 1986) identiﬁed these
polyploid cells as P-TGCs (Fig. 2B). Counting of these cells in
midline sections revealed a signiﬁcant 40% loss of P-TGCs at
E10.5 (36.377.1 versus 19.871.9; 10 WT v 16 Ascl2-Tg placental
sections from 5 litters; p¼0.0120; Fig. 2C, Supplemental Table 4).
Consistent with the loss of P-TGCs, RT-QPCR revealed a signiﬁcant
30% reduction in expression of Prl3d at E9.5 and E10.5 (Fig. 2D).
Expression of Prl3b1 (aka Pl2), a second gene expressed in P-TGC at
E9.5 and E10.5 (Simmons et al., 2008), was also markedly reduced,
by 70% and 40% respectively (Fig. 2D, Supplemental Table 4).
Hand1 and Prl2c, genes expressed in all or most of the TGC lineages
(Simmons et al., 2008; Scott et al., 2000), were not signiﬁcantly
altered suggesting the defect was not attributable to the loss of
other emergent TGC lineages. The loss of P-TGC was reciprocal to
the phenotype reported in response to reduced Ascl2 expression
(Guillemot et al., 1994; Tanaka et al., 1997). Markers associated
with the emerging spongiotrophoblast and glycogen cell lineages
were also measured (Fig. 2E). Tpbpa, expressed in the precursors of
the spongiotrophoblast, the glycogen cells, S-TGC, SpA-TGC and
50% of the P-TGC (Hu and Cross, 2011), was expressed at near
normal levels (Fig. 2E). Blimp1, Rgs5, Pcsk6 and Prl7b1, expressed in
the precursors of the glycogen cells, the SpA-TGC and the C-TGC
(Mould et al., 2012) or exclusively in the SpA TGC (Mould et al.,
2012) were expressed at near normal levels. Protocadherin 12
(Pcdh12), one of the earliest markers of the glycogen cell lineage
(Bouillot et al., 2006), was expressed at wild type levels at E9.5 but
elevated at E10.5, by 1.5-fold (Fig. 2E, Supplemental Table 4).
To further investigate the effects of the Ascl2 transgene on the
placental lineages, Ascl2-Tg placenta were histologically examined
at E14.5. H&E staining revealed an unexpected, distinct and dra-
matic loss of the junctional zone, where the glycogen and spon-
giotrophoblast cells normally reside (Fig. 3A). In situ hybridisation
with Tpbpa, exclusively expressed in both the spongiotrophoblast
and the glycogen cells (Lescisin et al., 1988), further highlighted
the dramatic loss of cells from the junctional zone (Fig. 3B). In situ
hybridisation with Psg17, an exclusive marker of the spongio-
trophoblast (Kromer et al., 1996), suggested a substantial loss of
this lineage from the junctional zone (Fig. 3C). In situ hybridisation
with Prl3b1, expressed in the spongiotrophoblast, C-TGC, P-TGC
and S-TGCs at E14.5 (Simmons et al., 2008), was also consistent
with a signiﬁcant loss of the spongiotrophoblast lineage from the
junctional zone, and further identiﬁed a degradation of the inter-
face between the junctional zone and maternal decidua consistent
with the loss of P-TGC from this region (Fig. 3D). What little re-
mained of the junctional zone stained for Periodic acid Schiff
(PAS), which distinguishes glycogen cells (Adamson et al., 2002),
suggesting that the junctional zone was primarily composed of
this cell type (Fig. 3E). There was an overall 40% decrease in
junctional zone area (Fig. 3F; Supplemental Table 5) and an in-
creased number of junctional zone-like clusters of cells present in
the labyrinth. While clusters were apparent in both WT and Ascl2-
Fig. 2. A reduction in the parietal trophoblast giant cell lineage. (A) Haematoxylin staining of midline placental sections at E10.5. Parietal trophoblast giant cells (P-TGC) are
indicated by dashed lines. Scale bars¼500 mm. (B) In situ hybridisation with a Prl3d (Pl1) riboprobe, which speciﬁcally marks P-TGCs at E10.5. Scale bars¼500 mm. (C) P-TGC
number per section at E10.5. N¼26. (D) Relative expression levels of key markers of P-TGC at E9.5 and E10.5. Prl3d1, Prl3b1 (aka Pl2), Prl2c (aka Plf) and Hand1 are all
expressed the P-TGC lineage at this time point. (E) Relative expression levels of markers of the emerging spongiotrophoblast (Tpbpa), glycogen cell (Pcdh12, Prl7b1), S-TGC,
SpA-TGC and C-TGC (Blimp1, Rgs5, Pcsk6, Prl7b1) lineages at E9.5 and E10.5. For the RT-qPCR analysis, N¼4 placenta per genotype (2 versus 2 from 2 independent litters);
error bars represent SEM. Statistical signiﬁcance calculated using t-test. NSP40.05, *Po0.05. Data for Fig. 2 in Supplemental Table 3.
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centa was 7-fold greater than WT (Fig. 3G; Supplemental Table 5).
The size of the clusters was similar between the two genotypes
(Fig. 3H; Supplemental Table 5) and they were Tpbpaþve/
Psg17ve/Prl3b1ve/Ascl2þve/PASþve (Fig. 3B–E, I; right pa-
nels). This analysis identiﬁed them as mislocalised glycogen cells.
At E18.5, just prior to term, the junctional zone was similarly
disorganised with clusters of mislocalised glycogen cells ob-
servable in the labyrinth of Ascl2-Tg placentae (Fig. 4A–C). As
quantiﬁed by area measurements of midline sections, the 12%
decrease in junctional zone at E18.5 was not signiﬁcantly different
to WT and there was small (11%) but signiﬁcant increase in la-
byrinth (Fig. 4D, Supplemental Table 6).
As a proxy for the representation of the different lineages, a RT-
QPCR analysis was performed (Fig. 5, Supplemental Table 7).
Tpbpa, Tpbpb and FMS-like tyrosine kinase 1 (Flt1), markers of the
junctional zone lineages at E14.5 (Henke et al., 2013; Hirashima
et al., 2003), were expressed at considerably lower levels in Ascl2-
Tg placenta compared to controls (Fig. 5A). Prl8a8, Prl3a1, Prl3c1,
Prl3a1, Prl7a2, Prl8a9, Psg17, Psg18, Psg19 and Psg21, all markers
exclusively or predominantly expressed in the spongiotrophoblast
(Simmons et al., 2008; McLellan et al., 2005), were expressed at
markedly lower levels in Ascl2-Tg placenta (Fig. 5B). Prl3b1, which
at E14.5 is expressed in P-TGC, C-TGC, S-TGC and spongiotropho-
blast (Simmons et al., 2008), was reduced (Fig. 5B). However two
other markers associated predominantly with the spongio-
trophoblast, Prl8a1 (SpT and P-TGCs) and Prl8a6 (SpT and C-TGCs)
(Simmons et al., 2008), were expressed at wild type levels. Thesedata essentially supported a loss of the spongiotrophoblast
lineage.
Markers of the glycogen cell lineage were also assessed
(Fig. 5C). Pcdh12 and Gap junction protein, beta 3 (Gjb3/Cx31), a
marker of glycogen cell maturation (Zheng-Fischhofer et al., 2007),
were expressed at near normal levels, however Prl7b1 and Prl2a1,
expressed predominantly but not exclusively in glycogen cells
(Simmons et al., 2008), were both signiﬁcantly elevated (Fig. 5C).
Prl7b1 is a marker of migrating glycogen cells and is also expressed
in SpA-TGC and C-TGC at E14.5, while Prl2a1 is expressed in P-TGC,
SpA-TGC and C-TGC, in addition to the glycogen cell lineage
(Simmons et al., 2008). Glucan (1,4-alpha-), branching enzyme 1
(Gbe1), involved in glycogen branching, was elevated. However,
Prl6a1, expressed in glycogen cells and SpA-TGCs, and other gly-
cogen metabolism enzymes, glycogenin (Gyg), glycogen synthase 1
(gys) and UDP-glucose pyrophosphorylase 2 (Ugp2), were not sig-
niﬁcantly elevated. These data supported a change in the nature of
the glycogen cell lineage rather than a signiﬁcant alteration in the
cellular contribution of this lineage to the placenta.
An analysis of the markers Hand1, Tle3 and Prl2c, genes ex-
pressed in all or most of the TGC lineages (Simmons et al., 2008;
Gasperowicz et al., 2013; Scott et al., 2000), and Ctsq, expressed in
just the S-TGC and Ch-TGC lineages (Rai and Cross, 2014), sug-
gested a near normal representation of these lineages (Fig. 5D).
Flk1, Dlx3, Tfeb, Syna, Synb, Gcm1 and Cebpa, all genes primarily or
exclusively expressed in the labyrinth at E14.5 (Simmons et al.,
2008; Hirashima et al., 2003; Steingrimsson et al., 1998; Berghorn
et al., 2005; Anson-Cartwright et al., 2000) were also expressed at
Fig. 3. A substantial loss of the spongiotrophoblast and mislocalisation of glycogen cells at E14.5. (A) HþE staining at E14.5 illustrating loss of the junctional zone. (B) In situ
hybridisation with a Tpbpa riboprobe, which speciﬁcally marks the spongiotrophoblast and glycogen cell lineages in the junctional zone, at E14.5. (C) In situ hybridisation
with a Psg17 riboprobe, which is expressed in just the spongiotrophoblast at E14.5. (D) In situ hybridisation with a Prl3b1 riboprobe, which is expressed in the P-TGC, C-TGC,
S-TGC and the spongiotrophoblast at E14.5, showing a degraded interface between the junctional zone and maternal decidua. (E) PAS staining of glycogen cells in the
junctional zone at E14.5. Three right hand images highlighting mislocalisation of glycogen cells in the labyrinth. (F) Midline section areas (mm2) occupied by the junctional
zone and labyrinth, and total area of both at E14.5. (G) Number of Tpbpaþve/Psg17ve/Prl3b1ve/PASþve/Ascl2þve clusters present in the labyrinth. (H) Total and average
area (mm2) occupied by Tpbpaþve/Psg17ve/Prl3b1ve/PASþve/Ascl2þve clusters in the labyrinth. (I) In situ hybridisation with an Ascl2 riboprobe, demonstrating
mislocalised cells express Ascl2. Scale bars¼1000 mm (two images on left); 350 mm (middle and adjacent right image) and 150 mm (far right image).
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sistent with a substantial loss of the spongiotrophoblast and
P-TGCs with limited consequence for the other placental lineages.
The loss of spongiotrophoblast was very marked in the Ascl2-Tg
placenta. Previously we have shown a direct relationship between
the spongiotrophoblast and the amount of stored placental gly-
cogen late in gestation, both of which were associated with fetal
growth restriction (Tunster et al., 2010, 2014, 2015; Salas et al.,
2004). To assess the consequences of elevated Ascl2, fetuses and
placenta were collected at E12.5, E14.5, E16.5 and E18.5. Theobserved ratios between Ascl2-Tg and non-transgenic fetuses were
not signiﬁcantly different to the expected ratios indicating no loss
of viability (Critical value 3.841 with p¼0.05 and DoF¼1; E12.5:
2.083, E14.5: 0.049, E16.5: 0.170 and E18.5: 0.865). Ascl2-Tg fetuses
were not signiﬁcantly different in weight to controls at E12.5,
E14.5, and E16.5 but at E18.5 there was a 6% (p¼0.00521) reduc-
tion in wet weight (Fig. 6A, Supplemental Table 8). Ascl2-Tg pla-
centae were signiﬁcantly lighter than controls at E12.5 and E14.5,
by 17% (p¼0.00898) and 11% (p¼9.29105) respectively, but
weights had recovered at E16.5 and E18.5 (Fig. 6B). As a
Fig. 4. Persistence of junctional zone phenotype at E18.5. (A) HþE staining at E18.5
illustrating loss of the junctional zone. Lower panels are higher magniﬁcation of the
regions indicated. (B) In situ hybridisation with a Tpbpa riboprobe, which speciﬁ-
cally marks the spongiotrophoblast and glycogen cell lineages, at E18.5. Lower
panels are higher magniﬁcation of the regions indicated. (C) PAS staining for gly-
cogen cells at E18.5. Lower panels are higher magniﬁcation of the regions indicated.
(D) Midline section areas (mm2) occupied by the junctional zone and labyrinth, and
total area of both at E18.5. Scale bars A–C¼1000 mm (upper panels); 400 mm (lower
panels).
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and E14.5 and lower at E18.5 (Fig. 6C). A biochemical determina-
tion of glycogen was performed at E14.5, E16.5 and E18.5. At E18.5,
there was a substantial (þ61%; mg) increase in the total amount of
glycogen present in Ascl2-Tg placenta (Fig. 6D). When expressed
relative to placental weight (mg/g), glycogen was signiﬁcantly in-
creased at both E16.5 (þ25%; p¼0.0458) and E18.5 (þ58%;
p¼0.00277).
Fetal growth restriction was very modest (6%) in comparison to
the placental defect. Our analysis of a different mouse model
(transgenic overexpression of Phlda2) with a similar substantial
loss of spongiotrophoblast revealed a fetal growth restriction
phenotype apparent on a 129 strain background and absent on a
BL6 background (Tunster et al., 2010, 2014, 2015) potentially ex-
plained by the less permissive F:P ratio in 129 mice (Tunster et al.,
2012). Ascl2-Tg was examined after 46 generations ofbackcrossing into 129. In initial studies, few plugged females were
pregnant when checked at E14.5 (Supplemental Table 9). When
the line was switched to a more nutrient-rich diet in a barrier unit,
pregnancy success rates improved (Supplemental Table 9) but
there was no difference in fetal weight between Ascl2-Tg fetuses
and WT littermates at E18.5 under these more favourable condi-
tions (Supplemental Table 10).
The dramatic reduction of the spongiotrophoblast lineage was
consistent with data demonstrating that ectopic expression of
Ascl2 in TS cells represses the expression of Tpbpa (Takao et al.,
2012) (Supplemental Table 1). However, a signiﬁcant loss of the
spongiotrophoblast lineage in vivo has been reported in associa-
tion with a 50% reduction in the expression of Ascl2 in Del7A1/þ
placenta (Oh-McGinnis et al., 2011). In this complex model, Phlda2
was expressed at two-fold higher than normal (Supplemental
Table 1). We have previously shown that two-fold elevation in the
expression of Phlda2 results in a substantial (50%) reduction of the
spongiotrophoblast (Tunster et al., 2010, 2014, 2015). Together
these data suggest that Ascl2 could regulate the spongiotropho-
blast indirectly via Phlda2. Phlda2 and Ascl2 co-localise to a subset
of cells with the developing chorio-allantoic placenta potentially
marking progenitors of the spongiotrophoblast (Oh-McGinnis
et al., 2011; Takao et al., 2012) (Fig. 7A). Ectopic expression of Ascl2
in TS cells results in lower expression of Phlda2 (Takao et al., 2012)
(Supplemental Table 1). In vivo, a similar elevation in Ascl2 did not
result in signiﬁcantly lower expression of Phlda2 (Fig. 7B). To ge-
netically test the relationship between Ascl2 and Phlda2, double
transgenic placenta carrying both the Ascl2 transgene and a ma-
ternally inherited targeted Phlda2 allele (Phlda2-/þ;Ascl2-Tg) were
generated. Both the Phlda2 loss-of-function placenta and the
double transgenic placenta possessed a markedly expanded junc-
tional zone, as evidenced by Tpbpa staining of E14.5 placental
sections (Fig. 7C). In the absence of Phlda2, Ascl2 was detectable by
in situ indicating that Ascl2 expression was not dependent on
Phlda2 (Fig. 7D). While is possible that the dominance of the
Phlda2 phenotype is a consequence of earlier events, these data are
consistent with Ascl2 acting via Phlda2 to suppress the expansion
of the spongiotrophoblast lineage (Fig. 8).4. Discussion
Ascl2 is a gene expressed from the maternal allele in the pla-
centa. Previous studies in mice examining the consequences of
reduced expression of Ascl2 have suggested a pivotal role for this
gene in repressing the expansion of the parietal trophoblast giant
cell lineage (Guillemot et al., 1995, 1994; Tanaka et al., 1997; Oh-
McGinnis et al., 2011). Here, we have conﬁrmed this directly in an
Ascl2 over expression model. We also highlight a novel role for the
Ascl2 in repressing the expansion of the spongiotrophoblast, a
function that depends on expression of a second maternally ex-
pressed imprinted gene, Phlda2. We previously reported that two-
fold expression of Phlda2 resulted in a loss of the spongiotropho-
blast associated with a signiﬁcant reduction in placental glycogen,
which led us to hypothesise a role for the spongiotrophoblast in
driving the accumulation of these stores (Tunster et al., 2010).
Here, we observed a similar loss of spongiotrophoblast but co-
incident with increased stores of placental glycogen late in ge-
station. Moreover, glycogen cells were markedly mislocalised to
the labyrinth. One interpretation of this data is that the mis-
localisation of the glycogen cells, in response to the loss of both
the P-TGC and the spongiotrophoblast, precludes the utilisation of
these stores resulting in late fetal growth restriction.
We have now identiﬁed three maternally expressed genes lo-
cated in a single, mechanistically distinct imprinted domain
(Fitzpatrick et al., 2002) that all act on the spongiotrophoblast
Fig. 5. Lineage analysis reveals a marked loss of the spongiotrophoblast and an increased representation of the glycogen cell lineage. (A) Quantitation of junctional zone
markers Tpbpa, Tpbpb and Flt1 at E14.5. (B) Quantitation of genes exclusively or predominantly expressed in the spongiotrophoblast at E14.5. (C) Quantitation of genes
exclusively or predominantly expressed in the glycogen cell lineage at E14.5. (D) Quantitation of genes exclusively or predominantly expressed in the TGC lineages at E14.5.
(E) Quantitation of genes exclusively or predominantly expressed in the labyrinth at E14.5. For the RT-qPCR analysis, N¼4 placenta per genotype (2 vs. 2 from 2 independent
litters); error bars represent SEM. Statistical signiﬁcance calculated using t-test. NSP40.05, *Po0.05, **Po0.01, ***Po0.005. Data for Fig. 5 in Supplemental Table 4.
S.J. Tunster et al. / Developmental Biology 418 (2016) 55–65 61lineage of the mouse placenta. Ascl2 and Phlda2 repress the ex-
pansion of this lineage while Cdkn1c is required for this lineage to
develop normally (Tunster et al., 2010, 2014, 2015, 2011; SalasFig. 6. Placental and fetal growth restriction but increased placental glycogen. (A) Transg
E14.5 (WT N¼42; Ascl2-Tg N¼40), E16.5 (WT N ¼25; Ascl2-Tg N¼28) and E18.5 (WT N
same time points. (C) Fetal:Placental (F:P) ratios at the same time points. (D) Biochemical
amount of glycogen (mg) E. Biochemical determination of placental glycogen at E14.5, E
Supplemental Table 5.et al., 2004). Additionally, Ascl2 and Cdkn1c are functionally im-
portant for the P-TGC and S-TGCs lineages, respectively. There is
some evidence that the IC2 imprinted domain encompassing theseenic versus non-transgenic fetal wet weights at E12.5 (WT N¼29; Ascl2-Tg N¼19),
¼41; Ascl2-Tg N ¼33). (B) Transgenic versus wild type placental wet weights at the
determination of placental glycogen at E14.5, E16.5 and E18.5 expressed as the total
16.5 and E18.5 expressed in relation to placental weight (mg/g). Data for Fig. 6 in
Fig. 7. Ascl2 requires Phlda2 to repress the expansion of the spongiotrophoblast lineage. (A) In situ hybridisation of sequential midline sections of wild type placenta at E10.5
with Ascl2 and Phlda2 riboprobes. The two genes are co-expressed in subset of cells at the base of the developing junctional zone (ﬁlled arrowheads) but not those located
near the P-TGC layer (white arrow). Scale bars 100 mm. (B) Quantitation of Phlda2 mRNA at E9.5, E10.5 and E14.5. (C) In situ hybridisation of midline sections of non-
transgenic, Ascl2-Tg, Phlda2/þ and Phlda2/þ; Ascl2-Tg double transgenic placenta with the junctional zone marker Tpbpa at E14.5. D. In situ hybridisation of midline
sections of non-transgenic, Ascl2-Tg, Phlda2/þ and Phlda2 /þ; Ascl2-Tg double transgenic placenta with an Ascl2 riboprobe at E14.5. Scale bars in C and D ¼1000 mm (upper
panels); 400 mm (lower panels).
S.J. Tunster et al. / Developmental Biology 418 (2016) 55–6562genes became imprinted after marsupials diverged from Eutherian
mammals (Suzuki et al., 2005, 2011.). It may be signiﬁcant that a
key difference between marsupials and Eutherians is the extent toFig. 8. Summary of gene expression data in relation to placental lineages. Genes indic
elevated in Ascl2-Tg placenta. Ascl2 requires Phlda2 to repress the expansion of the spowhich extra embryonic tissues support growth in utero with the
Eutherian newborn being substantially larger at term, relative to
the size of the mother, and distinctly more mature than theated in red are signiﬁcantly down and genes indicated in green are signiﬁcantly
ngiotrophoblast lineage.
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imprinted genes, including Esx1, Cited1, Plac1 and Nrk (maternally
expressed by virtue of their location on the paternally inactive
X-chromosome), that repress the spongiotrophoblast lineage and
at least two paternally expressed imprinted genes, Peg3 and Peg10,
predicted to increase the size of this compartment (John, 2013).
This convergence suggests that this lineage is a major site of par-
ental genomic conﬂict. The spongiotrophoblast is a major site of
production of placental lactogens (Simmons et al., 2008). Some
members of this extensive gene family (Prl3d and Prl3b1) have
been shown to induce the changes in the mother required for a
successful pregnancy (Bhattacharyya et al., 2002; Muller et al.,
1999). The spongiotrophoblast also manufactures pregnancy-spe-
ciﬁc glycoproteins (PSGs) which are another family of highly si-
milar secreted proteins thought to contribute in the protection of
the semiallotypic fetus from the maternal immune system, and
which also remodel placental and maternal vasculature (Kam-
merer et al., 2010; Wu et al., 2008). Essentially the spongio-
trophoblast is a hormone factory and the considerable drain on
maternal resources required to sustain the production of these
placental hormones may be why this lineage is so tightly regulated
by imprinting. Alternatively, this regulation may reﬂect the func-
tion of these hormones in pregnancy. Placental hormones are
manufactured in large quantities during pregnancy and act on the
maternal system to direct resources to support fetal growth. While
it remains to be determined whether such changes in gene ex-
pression in the placenta have a consequence for maternal phy-
siology in this model, this data provides further evidence that the
maternal and paternal genomes are involved in a continuing battle
over the endocrine function of the mouse placenta.
We have previously shown that the maternally expressed
Phlda2 gene limits the expansion of the spongiotrophoblast
alongside placental stunting, a loss of placental glycogen and fetal
growth restriction (Tunster et al., 2010, 2014, 2015). Similarly,
elevated Ascl2 also resulted in fetal growth restriction but, in
contrast to the Phlda2 transgenic model, placental glycogen stores
were markedly increased in the near term placenta when fetal
growth restriction was apparent. Moreover, there was a marked
appearance of clusters of glycogen cells in the labyrinth at a time
when these cells are normally migrating into the decidua. Ex-
pression of some glycogen cell markers, such as the marker of
migrating glycogen cells Prl7b1, was altered but the majority of
markers were expressed at similar levels to WT suggesting mis-
localisation from the junctional zone. A milder mislocalisation of
junctional zone cells was also apparent in our Phlda2 over-
expression model where there was also a loss of spongiotropho-
blast (Tunster et al., 2010) suggesting that the spongiotrophoblast
is important for maintaining the glycogen cells within the junc-
tional zone. Mislocalisation of glycogen cells in the Ascl2-Tg model
was considerably more severe than in our Phlda2 model suggest-
ing that the loss of P-TGC may further contribute to this pheno-
type. The presence of excess glycogen and fetal growth restriction
is not consistent with the suggestion that placental glycogen is
required to support late fetal growth (Coan et al., 2006). However,
these data can be reconciled if the release of glycogen into the
maternal system was prevented as a consequence of the mis-
localisation of glycogen cells into the labyrinth.
Fetal growth restriction was very modest (6%) on the BL6
background despite the rather dramatic loss of both P-TGC and
spongiotrophoblast cells. BL6 placenta have a higher F:P ratio and
are thought to have a greater reserve capacity to support fetal
growth compared to the 129 strain. We had great difﬁculty
breeding Ascl2-Tg into 129. Under standard conditions in a con-
ventional unit few plugged females were pregnant at E14.5. When
the line was rederived into a barrier unit where the mice were
maintained on an enriched diet, the pregnancy success rateimproved sufﬁciently to assess fetal growth but under these con-
ditions we observed no fetal growth restriction. The use of dif-
ferent diets under a different health status confounds the inter-
pretation of this data. Notably, targeted loss of function of the
placental lactogens Prl4a1 and Prl7b1 had no overt phenotypic
consequence under normal husbandry conditions but pregnancies
failed under stressed conditions (Ain et al., 2004; Bu et al., 2016).
There are 22 members of the Prl gene family (Simmons et al.,
2008). These data suggests an inherent redundancy in the func-
tions of members of the Prl family such that overt fetal compli-
cations manifest only when adverse conditions are combined with
reduced expression.
Both loss-of-function (Guillemot et al., 1995) and over-
expression of Ascl2 in vivo (Figs. 2D, and 5A) results in fewer cells
expressing Tpbpa. Ectopic overexpression of Ascl2 in TS cells also
resulted in low Tpbpa (Takao et al., 2012). These data suggest that
Ascl2 is both required for the development of Tpbpaþve lineages
and restrains their proliferation. In the Del7A1/þ model, in which
placenta express Ascl2 at 50% normal, at E9.5 placenta initially
appeared to have an increased number of cells expressing Tpbpa.
By E15.5 very few cells expressed this marker (Oh-McGinnis et al.,
2011). The Del7A1/þ model involves a 280 kb deletion of the IC1–
IC2 interval directly or indirectly disrupting the expression of
three imprinted genes in this region: Ascl2 (50%), Phlda2 (200%)
and Th (0%) (Oh-McGinnis et al., 2011). We have previously shown
that just two-fold expression of Phlda2 alone can reduce the size of
the spongiotrophoblast lineage by 50% (Tunster et al., 2010, 2014,
2015). The ﬁndings in these different models can be reconciled if
the spongiotrophoblast phenotype in the Del7A1/þ model is due to
elevated Phlda2 rather than a direct consequence of elevated Ascl2.
Previous studies have suggested a direct relationship between
Ascl2 and Phlda2 (Data summarised in Supplemental Table 1).
Ascl2 is co-expressed with Phlda2 in a subset of cells in the ecto-
placental cone at E7.5, E9.5 (Oh-McGinnis et al., 2011; Takao et al.,
2012) and E10.5 (Fig. 7A) where progenitors of the spongio-
trophoblast reside. Adenoviral-driven overexpression of Ascl2 in
trophoblast stem cells resulted in a 60% reduction in the expres-
sion of Phlda2 under stem cell culture conditions (Takao et al.,
2012). Conversely, knockdown of Ascl2 expression in TS cells (Ta-
kao et al., 2012) or reduced expression in vivo (Oh-McGinnis et al.,
2011) resulted in increased Phlda2 expression. In this current
study, we did not observe a statistically signiﬁcant reduction in
Phlda2 expression in vivo in response to overexpression of Ascl2.
When we genetically tested the relationship between Ascl2 and
Phlda2 by combining overexpression of Ascl2 with loss-of-ex-
pression of Phlda2, this resulted in a markedly expanded spon-
giotrophoblast similar to loss of expression of Phlda2 alone. This
tells us that, while both elevated Phlda2 (Tunster et al., 2010, 2014,
2015) and elevated Ascl2 repress the spongiotrophoblast, Ascl2 can
only do so in the presence of Phlda2 (Fig. 7C). These data are
consistent with Ascl2 functioning upstream of Phlda2 to control
the expansion of the spongiotrophoblast in a progenitor cell type
(Fig. 8).
In conclusion, we have demonstrated that overexpression of
the imprinted Ascl2 gene has considerable consequences for pla-
cental development, speciﬁcally for the P-TGC and spongio-
trophoblast lineages both of which express pregnancy-related
hormones. Either as a consequence of the reduced function of the
endocrine compartment or the failure in the appropriate migra-
tion of glycogen cells, elevated Ascl2 resulted in a late fetal growth
restriction. The presence of three imprinted genes within a single
mechanistically distinct imprinted domain that all act to regulate
placental lineages critical for the endocrine function of the pla-
centa suggest that the imprinting of this domain was key to the
switch to prolonged gestation and greater maturity at birth ob-
served in Eutherian mammals.
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